320 million yuan! The pharmaceutical company plans to transfer sun's over 40% stake

　　On the evening of May 11, Jingfeng Pharmaceuticals announced that it plans to transfer 43.01% of the 43.01% stake in Haimen Huiju Pharmaceutical Co., Ltd (hereinafter referred to as Haimen Huiju) held by its subsidiary Shanghai Jingfeng to the Fuyue Boize Industrial Investment Partnership (Limited Partnership) of Huzhou (hereinafter referred to as: Fu Yue Baize) and Fu Yuexin Industrial Investment Partnership (hereinafter referred to as Fu Yuexin) (hereinafter referred to as The Limited Partnership)
Data show that Haimen Huiju was founded in 2000, is an important API research and development production enterprises, the global pharmaceutical industry to provide CDMO services, while the production of high value-added API and advanced intermediates, the company entered the European market in 2007
At present, the company has more than 10 in the clinical late or waiting for approval to market innovative drugs, independently developed dozens of API Among them, in China, the United States, the European Union has declared 11 (3 to obtain drug approval), 18, 5 (3 received CEP certificate), and more than 10 products are in the research and development amplification or declaration preparation stage In addition, Haimen Huiju also has several European and American markets of the first imitation of raw materials, and hydrochloric acid Benapri raw materials, hydrochloric acid tabotan raw materials, hydrochloric acid Sichuan yuraw raw materials, mapasha star raw materials, vitamiabu raw materials and pimobenzene raw materials have been obtained GMP certificate
Financial data show that in the four-year period from 2016 to 2019, Haimen Huiju's revenue was 153 million, 185 million, 216 million and 304 million, respectively, with profits of 0.31 billion, 0.44 billion, 54.22 million and 45 million yuan, respectively For 2019 sales revenue increased by nearly 100 million yuan compared to 2018, but profits fell 17% The company recently said on the interactive platform, Haimen Huiju revenue increase profit decline is mainly due to the chemical park policy impact, environmental upgrading, rising raw material costs and other comprehensive reasons
In the eyes of the industry, Haimen Huiju still has strong research and development capabilities and CDMO capabilities, high business independence, Jingfeng Pharmaceuticals this transfer of part of its equity or in order to further promote the focus on core assets strategy, for its follow-up capital operation to open up a broader space for development
Haimen Huiju's newly introduced investors are closely related to domestic CRO giant Tiger Pharma Public information shows that the two real control per capita is Huang Hua Among them, Fu Yue Boze Limited Partners are Huang Hua, Tiger Pharmaceuticals, Li Yong, Yong Xiuguan by Zhaode Equity Investment Fund Center (Limited Partnership), Zhang Guoliang, Taige Pharmaceuticals directly held 31.25% of the capital contribution On February 26 this year, Tiger Pharma announced that it intends to pay 100 million yuan to Fu Yue-Baize
After this transfer, Jingfeng Pharmaceutical's shareholding in Haimen Huiju will be changed from 63.01% to 20% Jingfeng Pharmaceuticals said that the equity transfer will bring the interests of all parties together, help to establish a sound long-term incentive mechanism, and jointly pay attention to the long-term development of Haimen Huiju
Public information shows that Jingfeng Pharmaceuticals is a focus on the pharmaceutical and health industry, involved in pharmaceutical research and development, production, sales and other business, as well as pharmaceutical investment
In 2014, Jingfeng Pharma successfully went public, with net profit growth in the three years before it fell in 2017 and 2018, but it was still at a profitable level The 2019 annual report shows that Jingfeng Pharmaceutical's revenue and net profit both fell During the reporting period, the company achieved revenue of RMB1,344 million, down 48.02% YoY, and net profit was RMB883 million, down 572.56% YoY
Based on the performance situation in 2019, Jingfeng Pharmaceuticals this transfer of Haimen Huiju equity, is to dump the bag or for Haimen Huiju to prepare for the single listing, but also attracted the attention of all parties
From the point of view of the generic pharmaceutical industry in which Jingfeng Pharmaceutical is located, with the promotion of the policy of consistency evaluation and quantity purchasing, the pharmaceutical industry will face an important period of structural adjustment Jingfeng Pharmaceuticals said in its 2019 semi-annual report that Jingfeng Pharma will pay close attention to the industry situation, keep up with macroeconomic policy guidance, and actively promote strategic transformation in response to the increasingly competitive market situation, establish a "take the road of industrialization of generic drugs in line with international standards" basic strategy, on this basis, formulate long-term development plans, and implement a high-end characteristic imitation drug-based, multi-dimensional production pipeline and strategic layout